Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has entered into a partnership agreement with GP Capital to establish the GP Fund II, with a total fund size of RMB1.50 billion. The company will contribute RMB1,498.50 million, gaining de facto control over the fund, which will be consolidated into its financial statements. This transaction is classified as a connected transaction under Hong Kong Listing Rules, exempt from independent shareholders’ approval but subject to reporting and announcement requirements.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is based in the People’s Republic of China and is involved in various healthcare-related ventures.
Average Trading Volume: 1,157,942
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.97B
See more insights into 0874 stock on TipRanks’ Stock Analysis page.